Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Patients can expect to shed approximately 6-8% of their total body mass
Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]
Stopping them can lead to a significant drop in metabolism, which would likely counteract the benefits of a GLP-1 medication and could make you feel very unwell
Fiber rich foods help with digestive side effects and help maintain blood sugar while foods low in fat can minimize heart burn, nausea, and vomiting
15 SaeidinejadM.ElshabrawiA.SriphoosanaphanS.AndreolaF.MehtaG.AgarwalB.et al (2023)
US$ 20.35
US$ 23.55
US$ 21.25
US$ 28.55
US$ 20.30
US$ 25.10
US$ 26.17
US$ 29.13
US$ 23.80
US$ 29.85
US$ 21.72
